Venus receives GLP accreditation for its R&D centre

Venus Medicine Research Centre (VMRC), the R&D wing of Venus Remedies, a research-based global pharmaceutical company, has been accredited for Good Laboratory Practices (GLP) and norms on Organisation for Economic Cooperation and Development (OECD) Principles by the National GLP and Compliance Monitoring Authority (NGCMA). With this, VMRC has joined the list of top 25 testing laboratories in India and eight Indian pharma companies to have received GLP approval.

The certification is an attestation of the consistent reliability of the company’s R&D tests and calibration as well as its documented quality management system. Besides this, the GLP certification meets the company’s strategic vision to bring to the world novel breakthroughs that cater to critical care and super-specialty segments, including anti-infective (anti-microbial resistance), anti-cancer, neurology, pain management and wound care. Led by a team of 75 highly professional, trained and passionate scientists, VMRC is dedicated to developing novel and innovative research products on a par with global quality standards. The VMRC team has brought laurels to the country by securing over 90 patents for its research products from across the world, including countries like US, Australia, Japan, European Union constituents and many others.

“It is a matter of great pride for us to have received GLP certification for our Venus Medicine Research Centre. We are now the eighth pharma company in India with GLP accreditation. This accreditation follows the grant of full membership to India as an OECD member country. Thus, any R&D-related data generated in VMRC will be acceptable by the registration authorities of all the OECD member countries such as the US, Japan and various European countries,” said Dheeraj Aggarwal, Chief Financial Officer, Venus Remedies.

Dr Manu Chaudhary, Joint Managing Director, Venus Remedies and Director, Research, VMRC, said, “This GLP accreditation, one of the most coveted certifications for R&D capabilities, is yet another significant milestone in our efforts to ensure product quality, safety, reliability and excellence while preserving and improving human life through innovation. It gives our research an international credibility, which will translate into more business opportunities for the company and add to the reputation of our products and personnel.”

EP News BureauMumbai

Comments (0)
Add Comment